Merck: positive results in pneumococcal vaccine trials
(CercleFinance.com) - US drugmaker Merck on Tuesday announced positive results in two additional Phase 3 trials evaluating its investigational pneumococcal vaccine.
In one study, immune responses following vaccination with Pneumovax at month 13 were comparable in both vaccination groups for the 15 serotypes in V114, its experimental vaccine, the company said.
In a second study, V114 generated immune responses generally comparable to PCV13, an older vaccine, for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination, Merck said.
Pneumococcal disease in adults is on the rise worldwide, in part driven by disease-causing serotypes that are not targeted by the currently available vaccine.
There are over 90 different types of pneumococcal bacteria.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In one study, immune responses following vaccination with Pneumovax at month 13 were comparable in both vaccination groups for the 15 serotypes in V114, its experimental vaccine, the company said.
In a second study, V114 generated immune responses generally comparable to PCV13, an older vaccine, for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination, Merck said.
Pneumococcal disease in adults is on the rise worldwide, in part driven by disease-causing serotypes that are not targeted by the currently available vaccine.
There are over 90 different types of pneumococcal bacteria.
Copyright (c) 2020 CercleFinance.com. All rights reserved.